Cutuli B, Lemanski C, Fourquet A, de Lafontan B, Giard S, Lancrenon S, Meunier A, Pioud-Martigny R, Campana F, Marsiglia H, Mery E, Penault-Llorca F, Fondrinier E, de Lara C Tunon
Polyclinique Courlancy, Service de radiothérapie-oncologie, 38, rue Courlancy, 51100 Reims, France.
Bull Cancer. 2010 Mar;97(3):301-10. doi: 10.1684/bdc.2010.1048.
From March 2003 to April 2004, were prospectively collected in France 1,289 ductal carcinoma in situ (DCIS) with data on diagnosis, patient and tumour characteristics, and treatments. Median age was 56 years (range, 30-84). DCIS was diagnosed by mammography in 87.6% of patients. Mastectomy (M), conservative surgery alone (CS) and conservative surgery with radiotherapy (CS + RT) were performed in 30.5, 7.8 and 61.7% of patients, respectively. Sentinel node biopsy (SNB) and axillary dissection (AD) were performed in 21.3 and 10.4% of patients, respectively. Hormone therapy was administered to 13.4% of the patients. Nuclear grade was low in 21% of patients, intermediate in 38.5% and high in 40.5%. Excision was considered complete in 92% (CS) and 88.3% (CS + RT) of patients. Treatment modalities varied widely according to region: mastectomy rate, 20-37%; adjuvant RT, 84-96%; hormone treatment, 6-34%. Our survey on current DCIS management in France has highlighted correlations between pathological features (tumour size, margin, grade) and treatment options, with several similar variations to those observed in recent UK and US studies.
2003年3月至2004年4月，在法国前瞻性收集了1289例导管原位癌（DCIS）病例，这些病例包含诊断、患者及肿瘤特征以及治疗方面的数据。中位年龄为56岁（范围30 - 84岁）。87.6%的患者通过乳腺钼靶检查诊断为DCIS。分别有30.5%、7.8%和61.7%的患者接受了乳房切除术（M）、单纯保乳手术（CS）以及保乳手术加放疗（CS + RT）。分别有21.3%和10.4%的患者接受了前哨淋巴结活检（SNB）和腋窝清扫术（AD）。13.4%的患者接受了激素治疗。21%的患者核分级为低级别，38.5%为中级，40.5%为高级。92%（CS组）和88.3%（CS + RT组）的患者切除被认为是完整的。治疗方式因地区而异：乳房切除术率为20 - 37%；辅助放疗率为84 - 96%；激素治疗率为6 - 34%。我们对法国当前DCIS治疗情况的调查突出了病理特征（肿瘤大小、切缘、分级）与治疗选择之间的相关性，与近期英国和美国研究中观察到的几种相似变化情况相同。
